Prognostic value of the ratio of globally sclerotic glomeruli in patients with idiopathic IgA nephropathy

Read full text
Authors: Sinan Kazan, Savaş Öztürk, Müge Üzerk Kibar, Şeyda Gül Özcan, Raife Dilhan Alcelik Karacan, Necmi Eren, Mahmut Şükrü Gök, Kültiğin Türkmen, HAMAD DHEİR, Taner Baştürk, ERHAN TATAR, Ömer Faruk Akçay
+33 more Meltem Gürsu, Hakki Arikan, Sena Memnune ULU, Mehmet Deniz Ayli, İlhan Kurultak, Dilek Güven Taymez, Belda Dursun, Ramazan Öztürk, Sim Kutlay, Şebnem Karakan, Murvet Yilmaz, Di̇lek Torun, Kenan Turgutalp, Alper Azak, Zeki Aydin, Deren Oygar, Nedim Selcuk Yilmaz, Bülent Kaya, Zülfükar Yilmaz, Özcan Uzun, Murat Hayri Sipahioğlu, Melike Betül Öğütmen, Serap Yadigar, Aysegul Oruc, Mahmud İslam, Müge Doksan, Meryem Keleş, Mehmet Riza Altiparmak, Abdulkadir Çelik, Erkan Dervişoğlu, Rabia Hacer, Ezgi Çoşkun Yenigün, Onur Tunca
Cited by: 1
References: 19

Abstract

Abstract IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. We assessed whether the Ratio of Globally Sclerotic Glomeruli (RoGSG) on diagnostic biopsy predicts subsequent kidney outcomes in a nationwide, multi‑center registry. Among 326 adults with idiopathic IgAN (mean age 39.1 ± 12.8 years; 60.1% male), 43 patients (13.2%) met a 5 year composite outcome defined as any of: doubling of serum creatinine or ≥ 50% decline in eGFR from baseline, eGFR < 15 mL/min/1.73 m 2 , or initiation of kidney replacement therapy. Receiver operating characteristic analysis identified a RoGSG cutoff of 28.86% for predicting the composite outcome (AUC 0.917, 95% CI 0.885–0.949; sensitivity 93.0%; specificity 84.5%). Using this threshold, 47.6% of patients with RoGSG ≥ 28.86% versus 1.2% with RoGSG < 28.86% reached the composite outcome. In multivariable models adjusted for clinical and pathologic covariates, high RoGSG, grade 2 tubular atrophy/interstitial fibrosis, and non‑response to initial immunosuppression were independent predictors of adverse outcomes. The prognostic association of RoGSG persisted in key subgroups, including those with nephrotic syndrome and those with initial treatment response. These findings support RoGSG as a readily available histopathologic marker that may improve risk stratification in IgAN; however, prospective studies and external validation in independent cohorts are required before any clinical adoption.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Chronic Kidney Disease and Diabetes Vasculitis and related conditions

Publication details

Journal / source
Scientific Reports
Publisher
Springer Science and Business Media LLC
Volume
16
Issue
1
Pages
3178–3178
Publication date
7 January 2026
Language
EN